USC has received a $6m grant from the California Institute for Regenerative Medicine (CIRM) to advance a new gene therapy for ...

The California Institute for Regenerative Medicine has awarded a $6 million grant to USC investigators pioneering a new first ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Patients with this type of tumor who are treated aggressively with surgery, radiation and ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...

Experiments in mouse models showed the gene therapy strategy significantly reduced the tumor burden compared to untreated animals in two fast-growing, difficult-to-treat cancers: glioblastoma ...

Her writing focuses on gene editing technology, cell and gene therapies ... “This research is crucial because glioblastoma remains one of the most difficult cancers to treat, with a high rate of ...

Brain cancer is the second-leading cause of death in children in the developed world. For the children who survive, standard ...

The term MGMT-unmethylated glioblastoma refers to a genetic alteration of the brain cancer where the MGMT gene is not methylated ... RNA [mRNA] backbone therapy. The ability to achieve both ...

International collaborations, refined gene-editing protocols, and targeted immunologic maneuvers keep the cancer gene therapy ...